Gemcitabine-induced survival pathways

Gemcitabine-induced survival pathways refer to the adaptive molecular responses activated by cancer cells to survive the cytotoxic stress of gemcitabine treatment. Gemcitabine, a nucleoside analog, inhibits DNA synthesis, but its clinical efficacy is often hampered by the rapid induction of pro-survival cascades, including the Nuclear Factor-kappa B (NF-κB), Phosphoinositide 3-kinase (PI3K)/Akt, and Mitogen-Activated Protein Kinase (MAPK) pathways (Binenbaum et al., 2015, PubMed: 25893291). These pathways collectively suppress apoptosis and promote cell cycle progression, contributing to the high rate of chemoresistance observed in pancreatic ductal adenocarcinoma and non-small cell lung cancer (Arlt et al., 2003, PubMed: 12606483). The concept of "combination interaction" involves the strategic use of secondary agents, such as erlotinib or specific pathway inhibitors, to disrupt these survival signals and restore the apoptotic potential of gemcitabine (Ng et al., 2000, PubMed: 10885451). Understanding these pathways is essential for identifying biomarkers of resistance and developing multi-targeted therapeutic regimens that can overcome the limitations of gemcitabine monotherapy (Jia and Xie, 2015, PubMed: 25596311).

Other names

Gemcitabine resistance pathwaysGemcitabine-mediated survival signalingGemcitabine-induced chemoresistanceGemcitabine-induced survival signaling

Gemcitabine induces DNA damage and metabolic stress, which triggers the compensatory activation of pro-survival signaling pathways such as NF-κB and PI3K/Akt. Targeted inhibition of these pathways in combination with gemcitabine prevents this adaptive resistance and enhances the drug's ability to induce apoptosis.